Back to news
Portfolio – Jul 01, 2021

Sequana Medical announces positive results from second interim analysis of North American pivotal alfapump study – POSEIDON

Ghent, BELGIUM – 1 July 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces positive results from the second interim analysis of POSEIDON, the North American pivotal study of the alfapump for the treatment of recurrent or refractory ascites due to liver cirrhosis. These interim data from 26 patients in the Roll-In Cohort are in line with the previous interim dataii, including positive outcomes against all primary endpoints of the study and a rapid and persistent clinically important improvement in quality of life measures.

Find full press release here.

Latest News

Related News